Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: A FDG PET study

Lupus

Volumn 7, Issue 1, 1998, Pages 57-59

  Otte, A ^a,b   Weiner, S M ^b   Hoegerle, S ^b   Wolf, R ^b   Juengling, F D ^b   Peter, H H ^b   Nitzsche, E U ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cyclophosphamide; F 18 fluoro 2 deoxy D glucose positron emission tomography (FDG PET); Micro vessel vasculitis; Neuropsychiatric systemic lupus erythematosus (SLE); Prednisolone

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; BRAIN METABOLISM; CASE REPORT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MEMORY; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL DISORDER;

ADULT; BRAIN; CYCLOPHOSPHAMIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISOLONE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031973272     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678919651     Document Type: Article

References (14)

1. Harris EN, Hughes GRV Cerebral disease in systemic lupus erythematosus. Semin Immunopathol 1985; 8: 251-266.
2. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol1992; 19: 47-52.
3. Kassan SS, Lockshin MD. Central nervous system lupus erythematosus. The need for classification. Arthritis Rheum1979; 22: 1382-1385.
4. Sibbitt WL, Sibbitt RR Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 1993; 19: 851-868.
5. Hiraiwa M et al. Positron emission tomography in systemic lupus erythematosus: relation of cerebral vasculitis to PET findings. Am J Neuroradiol1983; 4: 541-543
6. Pinching AJ et al. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet1978; 1: 898-900.
7. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum1982; 25: 1271-1277.
8. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med1986; 27: 235-238.
9. McInness PM, Schuttinga J, Sanslone WR, Stark SP, Klippel JH. The economic impact of treatment of severe lupus nephritis with prednisolone and cyclophosphamide. Arthritis Rheum1994; 37: 1000-1006.
10. Brickenkamp R. Test d2. Aufmerksamkeits-Belastungs-Test. Hogrefe, Göttingen,1981.
11. Hillers F. DCS. Diagnosticum für Cerebralschädigung. Hans Huber, Göttingen,1993.
12. Otte A et al. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatrie symptoms: a controlled positron emission tomography study. Eur J Nucl Med1997; 24: 787-791.
13. Graham DG, Brierly JB. Vascular disorders of the central nervous system. In Neuropathology. Adams J. (ed.) London: Edward Arnold;1984: 125-207.
14. Critchley M. The Parietal Lobes London: Hafner, 1969.